A Modified APACHE II Score for Predicting Mortality of Variceal Bleeding

El Nibras M Abdelrahim*, Adam AM*, Ibnouf MAM*

Abstract

Introduction: Prediction of outcome of based on personal experience is subjective. There is a need for a method of prediction to suit our current state of practice.

Objectives: To evaluate a modified APACHE II system in predicting mortality in acute variceal bleeding.

Patients and methods: Prospective study conducted from June 2005 through September 2006 in the Ibn Sina Hospital Bleeding Centre ICU. Clinical and laboratory data for 102 patients were allotted a modified APACHE II score, a child-Pugh class and fed to SPSS to calculate predicted mortality.

Results: The mean (±SD) age 49.2(± 16.1) years. Male were 79(77.5%). Patients with liver cirrhosis and periportal fibrosis were 75 (73.5%) and 27 (26.5%) respectively. The mean predicted mortality was 22.8% while the actual mortality was 26.5% (27) patients. The mean modified APACHE II score among the deceased group was 19.04. Rate of deaths among liver cirrhosis patients was 12 (44.4%) with mean predicted mortality of 27.3%. Deaths among periportal fibrosis occur at mean modified APACHE II score 17.7 and mean predicted mortality of 20%. Seventeen patients had ICU stay ≥ 4 days. Ten out of them died (58.8%).

Conclusion: Modified APACHE II score is effective in predicting outcome of patients with variceal bleeding. Score of ≥ 15 points and long ICU stay are associated with high mortality.

Keywords: liver cirrhosis, periportal fibrosis, portal hypertension, schistosomiasis,

2- To calculate inspired oxygen; the oxygen saturation was noted from oximeter and converted through oxygen dissociation curve.

Objectives

To determine the effectiveness of a modified APACHE II score in predicting the outcome of patients, admitted to ICU of the GIT Bleeding Centre at Ibn Sina Hospital in Khartoum, suffering of acute oesophageal variceal bleeding and to find out high risk factors associated with such mortality.

Methods

This is a prospective study done between June 2005 and Sept. 2006. All patients with massive oesophageal variceal bleeding were considered for the study. Informed consents were obtained and ethical clearance was granted. Patients with upper GIT bleeding due to causes other than variceal bleeding and patients who do not meet the eligibility criteria of modified APACHE II score and Child-Pugh classification within the first 24 hours of admission were excluded. The studied population consists of 102 critically ill patients with oesophageal variceal bleeding.

Set up: This study was conducted at the ICU of GIT bleeding centre at Ibn Sina Hospital. The GIT Bleeding Centre consists of well equipped ICU, intermediate care unit with 4 beds, general ward, full equipped endoscopic theatre, blood bank, laboratory facilities, pharmacy, upper and lower GIT emergency endoscopic service and elective GIT manometry. The ICU staffs consist of 3 to 4

© Sudan JMS Vol. 2, No. 2, June 2007
sisters, one registrar, one medical officer, and one consultant per duty. It receives critically ill patients with upper and lower GIT bleeding who were referred from other hospitals.

Clinical and laboratory data conforming to the modified APACHE II score and Child-Pugh classification were collected in the first 24 hours of admission. This include age, sex, medical history, mean BP, pulse rate, temperature, RR, GCS, presence of ascites, jaundice, serum creatinine, total bilirubin, serum electrolytes, total WBC, Hb, oxygen saturation, prothrombin time and serum albumin.

**Statistical analysis**

Data were fed to Statistical Package of Social Sciences (SPSS) program for descriptive and analytic statistics. The level of significance was taken at $P < 0.05$.

**Results**

102 patients were studied. They were 79 (77.5%) males and 23 (22.5%) females with mean (±SD) age 49.2 (± 16.1) range (18–89) years. The cause of portal hypertension in this studied group was liver cirrhosis in 27(26.5%) patients, and periportal fibrosis in 75(73.5%) patients. Their modified APACHE II score ranged from 5 to 29 with mean (± SD) 14.96 (±5.3). Their predicted mortality ranged from 8% to 40% with mean of 22.8%. The actual mortality was (27) 26.5% patients. The modified APACHE II score among the deceased group ranged from 7 to 29 with a mean of 19. In contrast the modified APACHE II for the survival group, ranged from 5 to 23 with a mean of 13.6. However, patients who had modified APACHE II score ≥15 were 54(52%) patients but 23 patients out of them died.

Child-Pugh classification was also used as disease specific scoring system so as to find out its prediction of mortality. Child class A patients were 43 (42.2%) with only three deaths, which represented 2.9% of the studied population. Patients with Child class B were 38(37.3%) with 10 deaths, which represented 9.8% of the total mortality. Those with Child class C were 21(20.8%) patients with 14 deaths, which represented 13.7% of the total mortality (figure 1).

There were 27 patients with liver cirrhosis 12(44.4%) out of them died. Their modified APACHE II score ranged from 11 to 29 with a mean of 20 and mean predicted mortality rate 27.3%. Nine out of the 12 patients who died in the ICU were Child-Pugh classification class C. The rest of the deaths of cirrhosis were two with Child B class and only one patient with Child A class.

There were 75 patients with periportal fibrosis, 15 out of them died giving a mortality rate of 20%. Patients with periportal fibrosis showed modified APACHE II score predicted mortality rate of 17.7. Child-Pugh classification of deaths in this group were Child class B in eight(53.3%) patient, Child class C in five(33%) patients, and Child class A in two(13%) patients.

**Relationship between co-morbid diseases and deaths:**

1. **Patients with liver cirrhosis:**

   In 27 patients with liver cirrhosis, 21 (77.8%) patients had no associated disease. Nine out of those patients (42.9%) died. The remaining six patients (22.2%) with liver cirrhosis had associated co-morbid disease; three patients out of them (50%) died (Table 1).

<table>
<thead>
<tr>
<th>Total</th>
<th>Liver cirrhosis without co-morbid disease</th>
<th>Liver cirrhosis with co-morbid disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver cirrhosis died</td>
<td>6(22.2%)</td>
<td>12(57.1%)</td>
</tr>
<tr>
<td>Liver cirrhosis alive</td>
<td>21(77.8%)</td>
<td>9(42.9%)</td>
</tr>
</tbody>
</table>

2. **Patients with periportal fibrosis:**

   Total number of patients with periportal fibrosis was 75 patients. 55 (73.3%) of them had no associated disease. Eight patients from this group died and 47 patients remained alive. The number of patients with periportal fibrosis and associated co-morbid disease were 20(26.7%), seven out of them died and 13 patient remained alive (Table 2).
A Modified APACHE II score for predicting mortality of variceal bleeding, AbdelRahim E M  et al

Table (2) Relation of associated disease to mortality in patients with periportal fibrosis

<table>
<thead>
<tr>
<th>Total</th>
<th>Periportal fibrosis without disease</th>
<th>Periportal fibrosis with disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alive Died</td>
<td>55(73.3%) 20(26.7%)</td>
<td>47(85.5%) 8(14.5%) 13(65%) 7(35%)</td>
</tr>
</tbody>
</table>

In this cohort 63(61%) patients had Sengestaken’s tube as initial method for bleeding control, 20(19.6%) patients out of them died. Eighty-five (83.3%) patients underwent emergency sclerotherapy, 13(12%) of them died. Only 2(1.9%) patients underwent band ligation, with no death reported among them.

The ICU stay for the whole studied group ranged from 1 to 8 days with mean (± SD) 2.4 days (±1.64). The ICU stay in those who died, ranged from 1 to 8 days with mean (±DS) 3.4 days (± 2.1). There were 17(16.7%) patients with ICU stay 4 days; 10(58.8%) out of them died. In contrast, those with ICU stay < 4 days were 85(83.5%) patients and only 17(20%) of them died. The mean modified APACHE II score for those having ICU stay ≥ 4 days was 17.1, while for those having ICU stay < 4 days was 14.7.

Discussion

Mortality risk prediction in patients admitted to ICU is commonly used in clinical research and practice. It helps to improve accuracy when evaluating management policies, refine indications for admission to ICU and facilitate comparison of actual and predicted mortality in different series. Prediction of the outcome of patients admitted with massive variceal bleeding is difficult because of complexity of changing variables in the critical bleeder who is suffering from chronic liver disease and acute haemodynamic instability as well as other co-morbid diseases. Therefore, this complexity, suggests that a scoring system other than the simple Child-Pugh may improve the accuracy of prediction.

APACHE scoring system is widely used as an index of illness severity, for outcome prediction, research protocols, assessing ICU performance and quality of care. Despite its wide spread use little is known about its validity in patients admitted to ICU with massive acute variceal bleeding. We have done a comprehensive PubMed search and to the best of our knowledge there is no reported study comparing outcome of massive acute variceal bleeding in periportal fibrosis and cirrhosis. The present study attempted to evaluate the severity of acute variceal bleeding using locally modified APACHE II score.

In this study the mean predicted mortality was 22.8%, while the actual mortality was 26.5%. Therefore, our modified APACHE II score predicted mortality with 86 % accuracy. The predicted mortality is lower than actual mortality because most of the patients referred from other hospitals and APACHE II is subjected to time factor bias. These findings are in keeping with the literature that delays in admission and varying referral methods may result in an inaccurate prediction of outcome.

The mean modified APACHE II score among the deceased group was 19 while in the survival group was 13.6. This difference is statistically significant P 0.0001. The deceased group had significantly greater modified APACHE II score than survivals and this is obviously similar to other reports in the literature. Our study demonstrated that low modified APACHE II score predicts survival while high score predicts mortality.

Patients with modified APACHE II score ≥15 were 54(52%), out of them 23(42.6%) died. This means that there is increased risk of death when the score is ≥ 15. This is very much comparable with the results of the study, which was conducted by Being Wang et al in patients with bleeding gastric ulcer. Also our findings are comparable to that of Sein and Gecelter. The cutoff score of 15 has appropriate similar pattern of risk definition according to APACHE II score as was demonstrated in peritonitis.

There were 27 patients with liver cirrhosis, 12 out of them died with actual mortality rate of 44.4%. In this group of patients, the mean modified APACHE II score was 20, with mean predicted mortality 27.3%. Obviously the modified APACHE II score under estimated the risk of death in this group of patients. This could be explained by relative reasonable early stability subsequently followed by decompensation of the liver. On the other hand, applying the Child-Pugh classification to the patients who died from this particular group showed class C in nine patients, class B in two patients and class A in only one patient. The risk of death in patients with liver cirrhosis seems to correlate better with the Child-Pugh classification as a disease specific scoring system as reported previously. In contrast there were 75 patients with periportal fibrosis, 15 patients out of them died, with actual mortality
rate 20%. They showed mean modified APACHE II score 17.7, which is equal to mean predicted mortality 20%. Whereas in the same group, patients who died have Child-Pugh class B in 8 patients (53.3%), class C 5 patients (33%), and 2 patients with Child class A (13.3%).

The relationship between co-morbid diseases and death in 27 patients with liver cirrhosis in this study showed, 21 (77.8%) patients have no associated disease and six (22.2%) patients with associated diseases. In the former group nine (42.9%) patients died, while three (50%) patients from the latter group died. Although the figures are rather small in this study these high mortality rates obviously show that the risk of deaths is high among patients with liver cirrhosis irrespective of the absence or presence of associated diseases.

In contrast, the total number of patients with periportal fibrosis was 75 patients, 55 (73.3%) patients of them had no associated disease, eight (14.5%) patients from this group died. While patients with periportal fibrosis and co-morbid diseases were 20 (26.7%) patients ended with seven (35%) deaths. This observation shows that the co-morbid diseases increase the risk of death in patients with periportal fibrosis presenting with variceal bleeding.

In this study 63 (61%) patients had Sengstaken’s tube as first means for bleeding control, 20 (19.6%) patients out of them died (19.6%). All patients who had Sengstaken’s tube had significant bleeding at presentation. Such severe bleeding is commonly associated with shock, agitation or pre-coma which precludes sclerotherapy as first step in management. The above figures demonstrate that there is correlation between massive bleeding and death. On the other hand 85 (83.3%) patients underwent emergency sclerotherapy, 13 (12%) out of them died. Only two (1.9%) patients underwent rubber band ligation, with no death reported within this group. Band ligation has high cost, most of patients are farmer and too poor to pay for banding. For this reason such facilities are not always available in this centre, which deal with mass treatment with possible minimum cost.

The mean ICU stay for the whole studied group was 2.4 days. In comparison those who died had mean ICU stay 3.4 days. When we took 4 days as cutoff period we found that 17 (16.6%) patients had ICU stay ≥ 4 days with 10 (58.8%) deaths, while those with ICU stay < 4 days were 85 (83.5%) patients. 17 (20%) patients out of the later group died. Also the mean modified APACHE II score for those who had ICU stay ≥ 4 days was 17.1, while for those who had ICU stay < 4 days was 14.7. This shows clearly that patients with increase ICU stay ≥ 4 days had increased mortality rate and mean modified APACHE II score, which compares well with the study conducted by Siddiqui S, et al15.

We used locally modified APACHE II score, but looking in literature our study is similar to study conducted in Nigeria by A.R.K Adesunkanni et al who evaluate the use of locally modified APACHE II in African children with acute generalized peritonitis16. They dropped off the blood PH and oxygen tension and they scored the absent parameter as zero in accordance with recommendation of Meakin’s et al17. Because of high cost of repeated investigations in the first 24 hours most investigations were done once at admission and collection of data on admission only is economically effective, as compared to study done by HO KM et al18. They compared the admission and the 24 hours APACHE II worst scores in predicting hospital mortality and they found that substitution of 24 hours worst physiological variables with admission physiological variables maintained the over all discrimination ability of APACHE II in predicting mortality.

Conclusion

The modified APACHE II score is an effective tool in predicting outcome in patients with severe variceal bleeding. It is particularly useful in estimation risk of death in patients with portal hypertension and acute variceal bleeding secondary to periportal fibrosis. The modified APACHE II under predicts mortality by two folds in patients with variceal bleeding secondary to liver cirrhosis, which is better be scored by the Child-Pugh classification. Modified APACHEII score of ≥ 15 points is associated with high mortality. Long ICU stay, and Child-Pugh class C at presentation increase risk of death.

References


12. Schein M, Gecelter S. APACHE II score in massive upper gastro intestinal haemorrhage from peptic ulcer, prognostic value and potential clinical application: Br J surg 1989 ;76 :733-736


